|Awarded On||February 18, 2015|
|Title||Ewing's sarcoma, a homologous recombination defective disease|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Alexander Bishop|
|Cancer Sites||Childhood and Adolescent|
Ewing’s sarcoma occurs in children and young adults. The standard treatment, that effective 70% of the time, is a mixture of toxic chemotherapeutics and surgery. The toxicity in children is a concern since any damaging effects last a lifetime. Further, no successful alternatives exist beyond this first line treatment. Targeted therapy with less toxicity would be a major benefit, but requires a better understanding of Ewing’s sarcoma. We discovered that Ewing’s sarcoma has a defect in a DNA repair pathway called homologous recombination. This is the same kind of defect found in BRCA1 deficient breast cancer. Those cancers are sensitive to PARP1 inhibitors and so is Ewing’s sarcoma. We believe...